Media Thread, page-14626

The most obvious reason which Imugene is prohibited from promoting is the legal right of oncologists, indeed all medical practitioners to prescribe approved drugs for other indications called Off Label prescription.

If Imugene can find a registrational pathway to market for Vaxinia to treat bile duct cancer it then has a safe treatment that oncologists can OFF LABEL prescribed to any patient with cancer where they believe it may have clinical efficiency based on their professional judgment.
The safety of a drug is one of the primary considerations and they do not come much safer than Vaxinia.

I dare say any experienced biotech investor would understand this and realise that Lesley Chong is not permitted to promote off label prescribing but as they say a wink is as good as a nod to a blind man.

https://australianprescriber.tg.org.au/articles/ongoing-challenges-of-off-label-prescribing.html#:~:text=Box%201%20Guidance%20for%20off%2Dlabel%20prescribing&text=Only%20consider%20off%2Dlabel%20use,of%20off%2Dlabel%20medicine%20use.

My opinion only DYOR

Fact Finder